| GMM — GM2 Activator Protein | |
|---|---|
| Symbol | GMM |
| Full Name | GM2 Activator Protein |
| Chromosome | 5q31.3 |
| NCBI Gene | 755 |
| Ensembl | ENSG00000113595 |
| OMIM | 613512 |
| UniProt | P17900 |
| Diseases | Tay-Sachs Disease, GM2 Gangliosidosis, Lysosomal Storage Disorders |
| Expression | Brain, Liver, Kidney, Testis |
Gmm Gene Gm2 Activator Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GM2 Activator Protein (GMM) is a gene located on chromosome 5q31.3 that encodes a soluble protein essential for the degradation of GM2 ganglioside. This protein plays a critical role in lysosomal lipid metabolism and is essential for normal neuronal function.
The GM2 activator protein serves as a substrate-specific co-factor for the enzyme hexosaminidase A (Hex A). It binds to GM2 ganglioside and presents it to Hex A for hydrolysis. Without functional GM2 activator protein, GM2 ganglioside accumulates in neurons, leading to severe neurodegeneration.
Key functions include:
Mutations in the GMM gene cause AB variant of GM2 gangliosidosis, characterized by:
While primarily caused by HEXA mutations, GMM variants can modify the phenotype and severity of Tay-Sachs disease.
Recent research suggests that lipid metabolism dysregulation in neurons may contribute to more common neurodegenerative diseases including Alzheimer's and Parkinson's disease.
GMM is expressed in various tissues with highest expression in:
Understanding GMM function is important for developing:
The study of Gmm Gene Gm2 Activator Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.